Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis-Reference-Cited by-同舟云学术

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Published:2021-08-03 Issue:22 Volume:127 Page:4213-4220
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Maiti Abhishek¹^ORCID,DiNardo Courtney D.¹^ORCID,Qiao Wei²,Kadia Tapan M.¹^ORCID,Jabbour Elias J.¹^ORCID,Rausch Caitlin R.³^ORCID,Daver Naval G.¹^ORCID,Short Nicholas J.¹^ORCID,Borthakur Gautam¹,Pemmaraju Naveen¹^ORCID,Yilmaz Musa¹,Alvarado Yesid¹,Montalbano Kathryn S.¹,Wade Allison¹,Maduike Rita E.¹,Guerrero Julio A.¹,Vaughan Kenneth¹,Bivins Carol A.¹,Pierce Sherry¹,Ning Jing²^ORCID,Ravandi Farhad¹,Kantarjian Hagop M.¹^ORCID,Konopleva Marina Y.¹

Affiliation:

1. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

2. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas

3. Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas

Funder

University of Texas MD Anderson Cancer Center

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33814

Reference19 articles.

1. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia;Herold T;Leukemia,2020

2. International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

3. Treatment of Relapsed/Refractory Acute Myeloid Leukemia

4. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

5. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience;Frontiers in Oncology;2024-04-12

2. Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis;Frontiers in Oncology;2024-03-26

3. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony‐stimulating factor chemotherapy as a first‐line therapy for newly diagnosed acute myeloid leukemia: A propensity score–matched analysis;Cancer;2024-03-12

4. Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study;Leukemia & Lymphoma;2023-12-09

5. Venetoclax in adult acute myeloid leukemia;Biomedicine & Pharmacotherapy;2023-12